Toxicity as a result of immunostimulation by biologics

Bibliography

• PAUL W: Fundamental Immunology (5th edn). Paul W (Ed.), Lippincott Williams & Wilkins, Philadephia, USA (2003).
   Google Scholar
• ABBAS AK, LICHTMAN AH, POBER JS: Cellular and Molecular Immunology (4th edn). WB Saunders Company, Collingwood, Philadelphia, USA (2000).
   Google Scholar
• JANEWAY C, TRAVERS P, WALPORT M, SHLOMCHIK M: Immunobiology (6th edn). Janeway C (Ed.), Garland Science, Oxford, UK (2004).
   Google Scholar
• FEY GH, HOCKE GM, WILSON DR et al.: Cytokines and the Acute Phase Response of the Liver. In: The Liver: Biology and Pathobiology. Arias IM, Boyer JL, Fausto N et al. (Eds), Raven Press, New York, USA (1994).
   Google Scholar
• MIER JW, DINARELLO CA, ATKINS MB, PUNSAL PI, PERLMUTTER DH: Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells. J. Immunol. (1987) 139(4):1268-1272.
   PubMed Web of Science ®Google Scholar
• BAUMANN H, GAULDIE J: Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol. Biol. Med. (1990) 7(2):147-159.
   PubMedGoogle Scholar
• BAUMANN H, GAULDIE J: The acute phase response. Immunol. Today (1994) 15(2):74-80.
   PubMedGoogle Scholar
• MOSHAGE HJ, KLETER BE, VAN PELT JF, ROELOFS HM, KLEUSKENS JA, YAP SH: Fibrinogen and albumin synthesis are regulated at the transcriptional level during the acute phase response. Biochim. Biophys. Acta (1988) 950(3):450-454.
   PubMed Web of Science ®Google Scholar
• BEUTLER B, GREENWALD D, HULMES JD et al.: Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 316(6028):552-554.
   PubMed Web of Science ®Google Scholar
• LIAO WS, JEFFERSON LS, TAYLOR JM: Changes in plasma albumin concentration, synthesis rate, and mRNA level during acute inflammation. Am. J. Physiol. (1986) 251(6 Pt 1):C928-C934.
   PubMed Web of Science ®Google Scholar
• PERLMUTTER DH, DINARELLO CA, PUNSAL PI, COLTEN HR: Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J. Clin. Invest. (1986) 78(5):1349-1354.
   PubMed Web of Science ®Google Scholar
• GABAY C, KUSHNER I: Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. (1999) 340(6):448-454.
   PubMed Web of Science ®Google Scholar
• RAMADORI G, CHRIST B: Cytokines and the hepatic acute-phase response. Semin. Liver Dis. (1999) 19(2):141-155.
   PubMed Web of Science ®Google Scholar
• SHEDLOFSKY SI, ISRAEL BC, MCCLAIN CJ, HILL DB, BLOUIN RA: Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Invest. (1994) 94(6):2209-2214.
   PubMed Web of Science ®Google Scholar
• GANEY PE, LUYENDYK JP, MADDOX JF, ROTH RA: Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem. Biol. Interact. (2004) 150(1):35-51.
   PubMed Web of Science ®Google Scholar
• DIETSCH GN, DIPALMA CR, EYRE RJ et al.: Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol. Pathol. (2006) 34(1):39-51.
   PubMed Web of Science ®Google Scholar
• ROTH RA, LUYENDYK JP, MADDOX JF, GANEY PE: Inflammation and drug idiosyncrasy – is there a connection? J. Pharmacol. Exp. Ther. (2003) 307(1):1-8.
   PubMed Web of Science ®Google Scholar
• POBER JS, BEVILACQUA MP, MENDRICK DL, LAPIERRE LA, FIERS W, GIMBRONE MA Jr: Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J. Immunol. (1986) 136(5):1680-1687.
   PubMed Web of Science ®Google Scholar
• POBER JS, LAPIERRE LA, STOLPEN AH et al.: Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J. Immunol. (1987) 138(10):3319-3324.
   PubMed Web of Science ®Google Scholar
• COTRAN RS, POBER JS, GIMBRONE MA Jr et al.: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J. Immunol. (1988) 140(6):1883-1888.
   PubMed Web of Science ®Google Scholar
• DEJANA E, SPAGNUOLO R, BAZZONI G: Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb. Haemost. (2001) 86(1):308-315.
   PubMed Web of Science ®Google Scholar
• STOLPEN AH, GUINAN EC, FIERS W, POBER JS: Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am. J. Pathol. (1986) 123(1):16-24.
   PubMed Web of Science ®Google Scholar
• WOJCIAK-STOTHARD B, ENTWISTLE A, GARG R, RIDLEY AJ: Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J. Cell. Physiol. (1998) 176(1):150-165.
   PubMed Web of Science ®Google Scholar
• DEL MASCHIO A, ZANETTI A, CORADA M et al.: Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J. Cell Biol. (1996) 135(2):497-510.
   PubMed Web of Science ®Google Scholar
• VIAL T, DESCOTES J: Clinical toxicity of interleukin-2. Drug Saf. (1992) 7(6):417-433.
   PubMed Web of Science ®Google Scholar
• SIEGEL JP, PURI RK: Interleukin-2 toxicity. J. Clin. Oncol. (1991) 9(4):694-704.
   PubMed Web of Science ®Google Scholar
• DAMLE NK, DOYLE LV: IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J. Immunol. (1989) 142(8):2660-2669.
   PubMed Web of Science ®Google Scholar
• VANDENDRIES ER, DREWS RE: Drug-associated disease: hematologic dysfunction. Crit. Care Clin. (2006) 22(2):347-355, viii.
   PubMed Web of Science ®Google Scholar
• KOREN E, ZUCKERMAN LA, MIRE-SLUIS AR: Immune responses to therapeutic proteins in humans – clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. (2002) 3(4):349-360.
   PubMedGoogle Scholar
• FROST H: Antibody-mediated side effects of recombinant proteins. Toxicology (2005) 209(2):155-160.
   PubMed Web of Science ®Google Scholar
• BASSER RL, O'FLAHERTY E, GREEN M et al.: Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood (2002) 99(7):2599-2602.
   PubMed Web of Science ®Google Scholar
• SHIOZAKI H, MIYAWAKI S, KUWAKI T, HAGIWARA T, KATO T, MIYAZAKI H: Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood (2000) 95(6):2187-2188.
   PubMed Web of Science ®Google Scholar
• CASADEVALL N, NATAF J, VIRON B et al.: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. (2002) 346(7):469-475.
   PubMed Web of Science ®Google Scholar
• VERHELST D, ROSSERT J, CASADEVALL N, KRUGER A, ECKARDT KU, MACDOUGALL IC: Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet (2004) 363(9423):1768-1771.
   PubMed Web of Science ®Google Scholar
• GERSHON SK, LUKSENBURG H, COTE TR, BRAUN MM: Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med. (2002) 346(20):1584-1586.
   PubMed Web of Science ®Google Scholar
• CASADEVALL N, ROSSERT J: Importance of biologic follow-ons: experience with EPO. Best Pract. Res. Clin. Haematol. (2005) 18(3):381-387.
   PubMed Web of Science ®Google Scholar
• PETZ LD: Review: evaluation of patients with immune hemolysis. Immunohematol. (2004) 20(3):167-176.
   PubMedGoogle Scholar
• PETZ LD: Bystander immune cytolysis. Transfus. Med. Rev (2006) 20(2):110-140.
   PubMed Web of Science ®Google Scholar
• ROSSE WF, HILLMEN P, SCHREIBER AD: Immune-mediated hemolytic anemia. Hematology Am. Soc. Hematol. Educ. Program (2004):48-62.
   PubMedGoogle Scholar
• YAZDANBAKHSH K: Review: complement receptor 1 therapeutics for prevention of immune hemolysis. Immunohematol. (2005) 21(3):109-118.
   PubMedGoogle Scholar
• SILVERMAN GJ, WEISMAN S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. (2003) 48(6):1484-1492.
   PubMed Web of Science ®Google Scholar
• MARTIN SI, MARTY FM, FIUMARA K, TREON SP, GRIBBEN JG, BADEN LR: Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin. Infect. Dis. (2006) 43(1):16-24.
   PubMed Web of Science ®Google Scholar
• OSTERBORG A, KARLSSON C, LUNDIN J, KIMBY E, MELLSTEDT H: Strategies in the management of alemtuzumab-related side effects. Semin. Oncol. (2006) 33(2 Suppl. 5):S29-S35.
   PubMed Web of Science ®Google Scholar
• WEISS G: Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. (2002) 16(2):87-96.
   PubMed Web of Science ®Google Scholar
• CASH JM, SEARS DA: The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am. J. Med. (1989) 87(6):638-644.
   PubMed Web of Science ®Google Scholar
• JONGEN-LAVRENCIC M, PEETERS HR, WOGNUM A, VREUGDENHIL G, BREEDVELD FC, SWAAK AJ: Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J. Rheumatol. (1997) 24(8):1504-1509.
   PubMed Web of Science ®Google Scholar
• BRON D, MEULEMAN N, MASCAUX C: Biological basis of anemia. Semin. Oncol. (2001) 28(2 Suppl. 8):1-6.
   PubMed Web of Science ®Google Scholar
• PAPADAKI HA, KRITIKOS HD, VALATAS V, BOUMPAS DT, ELIOPOULOS GD: Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood (2002) 100(2):474-482.
   PubMed Web of Science ®Google Scholar
• MEANS RT Jr, KRANTZ SB: Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor. Exp. Hematol. (1996) 24(2):204-208.
   PubMed Web of Science ®Google Scholar
• MEANS RT Jr, KRANTZ SB, LUNA J, MARSTERS SA, ASHKENAZI A: Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood (1994) 83(4):911-915.
   PubMed Web of Science ®Google Scholar
• MEANS RT Jr, KRANTZ SB: Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J. Clin. Invest. (1993) 91(2):416-419.
   PubMed Web of Science ®Google Scholar
• MEANS RT Jr: Recent developments in the anemia of chronic disease. Curr. Hematol. Rep. (2003) 2(2):116-121.
   PubMedGoogle Scholar
• GANSER A, CARLO-STELLA C, GREHER J, VOLKERS B, HOELZER D: Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood (1987) 70(4):1173-1179.
   PubMed Web of Science ®Google Scholar
• WANG Q, MIYAKAWA Y, FOX N, KAUSHANSKY K: Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood (2000) 96(6):2093-2099.
   PubMed Web of Science ®Google Scholar
• ONG JP, YOUNOSSI ZM: Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve. Clin. J. Med. (2004) 71(Suppl. 3):S17-S21.
   PubMed Web of Science ®Google Scholar
• KOWDLEY KV: Hematologic side effects of interferon and ribavirin therapy. J. Clin. Gastroenterol. (2005) 39(Suppl. 1):S3-S8.
   PubMed Web of Science ®Google Scholar
• ULICH TR, DEL CASTILLO J, NI RX, BIKHAZI N, CALVIN L: Mechanisms of tumor necrosis factor alpha-induced lymphopenia, neutropenia, and biphasic neutrophilia: a study of lymphocyte recirculation and hematologic interactions of TNF alpha with endogenous mediators of leukocyte trafficking. J. Leukoc. Biol. (1989) 45(2):155-167.
   PubMed Web of Science ®Google Scholar
• JANKA GE: Hemophagocytic lymphohistiocytosis. Hematology (2005) 10(Suppl. 1):104-107.
   PubMed Web of Science ®Google Scholar
• FUJIWARA F, HIBI S, IMASHUKU S: Hypercytokinemia in hemophagocytic syndrome. Am J. Pediatr. Hematol. Oncol. (1993) 15(1):92-98.
   PubMedGoogle Scholar
• TSUDA H: Hemophagocytic syndrome (HPS) in children and adults. Int. J. Hematol. (1997) 65(3):215-226.
   PubMed Web of Science ®Google Scholar
• EMMENEGGER U, REIMERS A, FREY U et al.: Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med. Wkly (2002) 132(17-18):230-236.
   PubMed Web of Science ®Google Scholar
• FISMAN DN: Hemophagocytic syndromes and infection. Emerg. Infect. Dis. (2000) 6(6):601-608.
   PubMed Web of Science ®Google Scholar
• RISDALL RJ: Pathologic anatomy: virus-associated hemophagocytic syndrome. Minn. Med. (1980) 63(12):879-880.
   PubMedGoogle Scholar
• RISDALL RJ, BRUNNING RD, HERNANDEZ JI, GORDON DH: Bacteria-associated hemophagocytic syndrome. Cancer (1984) 54(12):2968-2972.
   PubMed Web of Science ®Google Scholar
• SHIMAZAKI C, INABA T, OKANO A et al.: Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS. Intern. Med. (2001) 40(9):878-882.
   PubMed Web of Science ®Google Scholar
• ARICO M, DANESINO C, PENDE D, MORETTA L: Pathogenesis of haemophagocytic lymphohistiocytosis. Br. J. Haematol. (2001) 114(4):761-769.
   PubMed Web of Science ®Google Scholar
• HURWITZ N, PROBST A, ZUFFEREY G et al.: Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leuk. Lymphoma (1996) 20(3-4):337-340.
   PubMed Web of Science ®Google Scholar
• VAN GILS FC, MULDER AH, VAN DEN BOS C, BURGER H, VAN LEEN RW, WAGEMAKER G: Acute side effects of homologous interleukin-3 in rhesus monkeys. Am. J. Pathol. (1993) 143(6):1621-1633.
   PubMed Web of Science ®Google Scholar
• ESTEVE E, RICART W, FERNANDEZ-REAL JM: Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. (2005) 24(1):16-31.
   PubMed Web of Science ®Google Scholar
• KHOVIDHUNKIT W, KIM MS, MEMON RA et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. (2004) 45(7):1169-1196.
   PubMed Web of Science ®Google Scholar
• NONOGAKI K, FULLER GM, FUENTES NL et al.: Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology (1995) 136(5):2143-2149.
   PubMed Web of Science ®Google Scholar
• GRUNFELD C, DINARELLO CA, FEINGOLD KR: Tumor necrosis factor-alpha, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. Metabolism (1991) 40(9):894-898.
   PubMed Web of Science ®Google Scholar
• SWORDS JENNY N, MANN KG: Thrombin. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ et al. (Eds), Lippincott Williams and Wilkins, Philadelphia, USA (2001):171-189.
   Google Scholar
• COLMAN RW, CLOWES AW, GEORGE JN, HIRSH J, MARDER VJ: Overview Of Hemostasis. In: Hemostasis And Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ et al. (Eds), Lippincott Williams and Wilkins, Philadelphia, USA (2001):3-16.
   Google Scholar
• ESMON CT: Inflammation and thrombosis: the impact of inflammation on the protein C anticoagulant pathway. Haematologica (1995) 80(Suppl. 2):49-56.
   PubMedGoogle Scholar
• LEVI M, KELLER TT, VAN GORP E, TEN CATE H: Infection and inflammation and the coagulation system. Cardiovasc. Res. (2003) 60(1):26-39.
   PubMed Web of Science ®Google Scholar
• ESMON CT: Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Clin. Haematol. (1994) 7(3):453-468.
   PubMed Web of Science ®Google Scholar
• OKAJIMA K: Regulation of inflammatory responses by natural anticoagulants. Immunol. Rev. (2001) 184:258-274.
   PubMed Web of Science ®Google Scholar
• BECKER BF, HEINDL B, KUPATT C, ZAHLER S: Endothelial function and hemostasis. Z. Kardiol. (2000) 89(3):160-167.
   PubMedGoogle Scholar
• FIRST MR, SCHROEDER TJ, HARIHARAN S: OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy). Transplant. Proc. (1993) 25(2 Suppl. 1):25-26.
   PubMed Web of Science ®Google Scholar
• CHRISTIANSEN NP, SKUBITZ KM, NATH K, OCHOA A, KENNEDY BJ: Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2. Am. J. Med. (1988) 84(6):1072-1075.
   PubMed Web of Science ®Google Scholar
• NAIR S, ERNSTOFF MS, BAHNSON RR et al.: Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology (1992) 39(2):169-172.
   PubMed Web of Science ®Google Scholar
• PALMER PA, VINKE J, EVERS P et al.: Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur. J. Cancer (1992) 28A(6-7):1038-1044.
   PubMed Web of Science ®Google Scholar
• ZELTSER R, VALLE L, TANCK C, HOLYST MM, RITCHLIN C, GASPARI AA: Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch. Dermatol. (2001) 137(7):893-899.
   PubMed Web of Science ®Google Scholar
• SAMUEL L, LOWENSTEIN EJ: Recurrent injection site reactions from interferon beta 1-b. J. Drugs Dermatol. (2006) 5(4):366-367.
   PubMedGoogle Scholar
• GOODKIN DE: Interferon beta-1b. Lancet (1994) 344(8938):1702-1703.
   PubMedGoogle Scholar
• LANGFORD CA: Vasculitis. J. Allergy Clin. Immunol. (2003) 111(Suppl. 2):S602-S612.
   PubMed Web of Science ®Google Scholar
• DEREURE O, NAVARRO R, ROSSI JF, GUILHOU JJ: Rituximab-induced vasculitis. Dermatology (2001) 203(1):83-84.
   PubMed Web of Science ®Google Scholar
• GALARIA NA, WERTH VP, SCHUMACHER HR: Leukocytoclastic vasculitis due to etanercept. J. Rheumatol. (2000) 27(8):2041-2044.
   PubMed Web of Science ®Google Scholar
• ADAMS GP,WEINER LM: Monoclonal antibody therapy of cancer. Nat. Biotechnol. (2005) 23(9):1147-1157.
   PubMed Web of Science ®Google Scholar
• AGERO AL, DUSZA SW, BENVENUTO-ANDRADE C, BUSAM KJ, MYSKOWSKI P, HALPERN AC: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J. Am. Acad. Dermatol. (2006) 55(4):657-670.
   PubMed Web of Science ®Google Scholar
• YANO S, KONDO K, YAMAGUCHI M et al.: Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res. (2003) 23(5A):3639-3650.
   PubMed Web of Science ®Google Scholar
• LAUX I, JAIN A, SINGH S, AGUS DB: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer (2006) 94(1):85-92.
   PubMed Web of Science ®Google Scholar
• MORSE L, CALARESE P: EGFR-targeted therapy and related skin toxicity. Semin. Oncol. Nurs. (2006) 22(3):152-162.
   PubMedGoogle Scholar
• COHEN LF, BALOW JE, MAGRATH IT, POPLACK DG, ZIEGLER JL: Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am. J. Med. (1980) 68(4):486-491.
   PubMed Web of Science ®Google Scholar
• BARTON JC: Tumor lysis syndrome in nonhematopoietic neoplasms. Cancer (1989) 64(3):738-740.
   PubMed Web of Science ®Google Scholar
• COPE D: Tumor lysis syndrome. Clin. J. Oncol. Nurs. (2004) 8(4):415-416.
   PubMedGoogle Scholar
• HANDE KR, GARROW GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am. J. Med. (1993) 94(2):133-139.
   PubMed Web of Science ®Google Scholar
• HUTCHERSON DA, GAMMON DC, BHATT MS, FANEUF M: Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy (2006) 26(2):242-247.
   PubMed Web of Science ®Google Scholar
• JABR FI: Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Int. J. Hematol. (2005) 82(4):312-314.
   PubMed Web of Science ®Google Scholar
• JENSEN M, WINKLER U, MANZKE O, DIEHL V, ENGERT A: Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann. Hematol. (1998) 77(1-2):89-91.
   PubMed Web of Science ®Google Scholar
• REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83(2):435-445.
   PubMed Web of Science ®Google Scholar
• TEDDER TF, CLEMENT LT, COOPER MD: Development and distribution of a human B cell subpopulation identified by the HB-4 monoclonal antibody. J. Immunol. (1985) 134(3):1539-1544.
   PubMed Web of Science ®Google Scholar
• HUHN D, VON SCHILLING C, WILHELM M et al.: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 98(5):1326-1331.
   PubMed Web of Science ®Google Scholar
• BYRD JC, MURPHY T, HOWARD RS et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. (2001) 19(8):2153-2164.
   PubMed Web of Science ®Google Scholar
• US FDA. Rituxan label for BLA No. 103705 (2006).
   Google Scholar
• SMITH JA, BLUESTONE JA: T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr. Opin. Immunol. (1997) 9(5):648-654.
   PubMed Web of Science ®Google Scholar
• GASTON RS, DEIERHOI MH, PATTERSON T et al.: OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int. (1991) 39(1):141-148.
   PubMed Web of Science ®Google Scholar
• FERRAN C, SHEEHAN K, DY M et al.: Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. (1990) 20(3):509-515.
   PubMed Web of Science ®Google Scholar
• WING MG, MOREAU T, GREENWOOD J et al.: Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. (1996) 98(12):2819-2826.
   PubMed Web of Science ®Google Scholar
• MOREAU T, COLES A, WING M et al.: Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 119(Pt 1):225-237.
   PubMed Web of Science ®Google Scholar
• PRUZANSKI W, UROWITZ MB, GROUIX B, VADAS P: Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis. J. Rheumatol. (1995) 22(10):1816-1819.
   PubMed Web of Science ®Google Scholar
• WINKLER U, JENSEN M, MANZKE O, SCHULZ H, DIEHL V, ENGERT A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood (1999) 94(7):2217-2224.
   PubMed Web of Science ®Google Scholar
• ERTEL W, MORRISON MH, WANG P, BA ZF, AYALA A, CHAUDRY IH: The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann. Surg. (1991) 214(2):141-148.
   PubMed Web of Science ®Google Scholar
• PANELLI MC, WHITE R, FOSTER M et al.: Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. (2004) 2(1):17.
   PubMedGoogle Scholar
• MARSH CB, WEWERS MD: The pathogenesis of sepsis. Factors that modulate the response to gram-negative bacterial infection. Clin. Chest Med. (1996) 17(2):183-197.
   PubMed Web of Science ®Google Scholar
• GUAN Y, POON LL, CHEUNG CY et al.: H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. USA (2004) 101(21):8156-8161.
   PubMed Web of Science ®Google Scholar
• DE JONG MD, SIMMONS CP, THANH TT et al.: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. (2006) 12(10):1203-1207.
   PubMed Web of Science ®Google Scholar
• YUEN KY, WONG SS: Human infection by avian influenza A H5N1. Hong Kong Med. J. (2005) 11(3):189-199.
   PubMedGoogle Scholar
• SUNTHARALINGAM G, PERRY MR, WARD S et al.: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN-1412. N. Engl. J. Med. (2006) 355(10):1018-1028.
   PubMed Web of Science ®Google Scholar
• PICHLER WJ: Adverse side-effects to biological agents. Allergy (2006) 61(8):912-920.
   PubMed Web of Science ®Google Scholar
• NAISBITT DJ, GORDON SF, PIRMOHAMED M, PARK BK: Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. (2000) 23(6):483-507.
   PubMed Web of Science ®Google Scholar
• PICHLER WJ: Drug-induced autoimmunity. Curr. Opin. Allergy Clin. Immunol. (2003) 3(4):249-253.
   PubMedGoogle Scholar
• ARIMURA K, ARIMA N, KUKITA T et al.: Fatal splenic rupture caused by infiltration of adult T cell leukemia cells. Acta Haematol. (2005) 113(4):255-257.
   PubMed Web of Science ®Google Scholar
• SECKIN D, DURUSOY C, SAHIN S: Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr. Dermatol. (2004) 21(5):577-579.
   PubMed Web of Science ®Google Scholar
• SOLANS R, BOSCH JA, ESTEBAN I, VILARDELL M: Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin. Exp. Rheumatol. (2004) 22(5):625-628.
   PubMed Web of Science ®Google Scholar
• NIEWOLD TB, SWEDLER WI: Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin. Rheumatol. (2005) 24(2):178-181.
   PubMed Web of Science ®Google Scholar
• DOI F, KAKIZAKI S, TAKAGI H et al.: Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. (2005) 25(2):242-246.
   PubMed Web of Science ®Google Scholar
• FLOREANI A, CHIARAMONTE M, GREGGIO NA et al.: Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. Ital. J. Gastroenterol. Hepatol. (1998) 30(1):71-76.
   PubMedGoogle Scholar
• LABBADIA G, MARTOCCHIA A, MAMMARELLA A et al.: Association between human leukocyte antigen (HLA) and interferon- induced thyroid diseases in four patients with HCV-related chronic hepatitis. Neuro Endocrinol. Lett. (2005) 26(2):109-112.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, PASCUAL V: Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity (2006) 25(3):383-392.
   PubMed Web of Science ®Google Scholar
• BLANCO P, PALUCKA AK, GILL M, PASCUAL V, BANCHEREAU J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 294(5546):1540-1543.
   PubMed Web of Science ®Google Scholar
• BENNETT L, PALUCKA AK, ARCE E et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. (2003) 197(6):711-723.
   PubMed Web of Science ®Google Scholar
• GREENWALD RJ, FREEMAN GJ, SHARPE AH: The B7 family revisited. Annu. Rev. Immunol. (2005) 23:515-548.
   PubMed Web of Science ®Google Scholar
• PEGGS KS, QUEZADA SA, KORMAN AJ, ALLISON JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. (2006) 18(2):206-213.
   PubMed Web of Science ®Google Scholar
• SHAHINIAN A, PFEFFER K, LEE KP et al.: Differential T cell costimulatory requirements in CD28-deficient mice. Science (1993) 261(5121):609-612.
   PubMed Web of Science ®Google Scholar
• GREEN JM, NOEL PJ, SPERLING AI et al.: Absence of B7-dependent responses in CD28-deficient mice. Immunity (1994) 1(6):501-508.
   PubMed Web of Science ®Google Scholar
• TIVOL EA, BORRIELLO F, SCHWEITZER AN, LYNCH WP, BLUESTONE JA, SHARPE AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3(5):541-547.
   PubMed Web of Science ®Google Scholar
• CHAMBERS CA, SULLIVAN TJ, ALLISON JP: Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 7(6):885-895.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100(14):8372-8377.
   PubMed Web of Science ®Google Scholar
• HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA (2003) 100(8):4712-4717.
   PubMed Web of Science ®Google Scholar
• ATTIA P, PHAN GQ, MAKER AV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. (2005) 23(25):6043-6053.
   PubMed Web of Science ®Google Scholar
• SANDERSON K, SCOTLAND R, LEE P et al.: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA-51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. (2005) 23(4):741-750.
   PubMed Web of Science ®Google Scholar
• RIBAS A, CAMACHO LH, LOPEZ-BERESTEIN G et al.: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. (2005) 23(35):8968-8977.
   PubMed Web of Science ®Google Scholar
• BLANSFIELD JA, BECK KE, TRAN K et al.: Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. (2005) 28(6):593-598.
   PubMed Web of Science ®Google Scholar
• ROBINSON MR, CHAN CC, YANG JC et al.: Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J. Immunother. (2004) 27(6):478-479.
   PubMed Web of Science ®Google Scholar
• VILCEK J: Fifty years of interferon research: aiming at a moving target. Immunity (2006) 25(3):343-348.
   PubMed Web of Science ®Google Scholar
• SMITH PL, LOMBARDI G, FOSTER GR: Type I interferons and the innate immune response – more than just antiviral cytokines. Mol. Immunol. (2005) 42(8):869-877.
   PubMed Web of Science ®Google Scholar
• KUNZI MS, PITHA PM: Interferon targeted genes in host defense. Autoimmunity (2003) 36(8):457-461.
   PubMed Web of Science ®Google Scholar
• KATZE MG, HE Y, GALE M Jr: Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. (2002) 2(9):675-687.
   PubMed Web of Science ®Google Scholar
• ROSEWICZ S, DETJEN K, SCHOLZ A, VON MARSCHALL Z: Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology (2004) 80(Suppl. 1):85-93.
   PubMedGoogle Scholar
• DOWDING C, GORDON M, GUO AP et al.: Potential mechanisms of action of interferon-alpha in CML. Leuk. Lymphoma (1993) 11(Suppl. 1):185-191.
   PubMed Web of Science ®Google Scholar
• BOSE A, GHOSH D, PAL S, MUKHERJEE KK, BISWAS J, BARAL R: Interferon alpha2b augments suppressed immune functions in tobacco-related head and neck squamous cell carcinoma patients by modulating cytokine signaling. Oral Oncol. (2006) 42(2):161-171.
   PubMed Web of Science ®Google Scholar
• OSTENSEN M,FORRE O: Modulation of human natural killer cell function by cytokines and rheumatic disease. Scand. J. Rheumatol. Suppl. (1988) 76:183-188.
   PubMedGoogle Scholar
• BARTON ES, LUTZKE ML, ROCHFORD R, VIRGIN HWT: Alpha/beta interferons regulate murine gammaherpesvirus latent gene expression and reactivation from latency. J. Virol. (2005) 79(22):14149-14160.
   PubMed Web of Science ®Google Scholar
• WINDISCH MP, FRESE M, KAUL A, TRIPPLER M, LOHMANN V, BARTENSCHLAGER R: Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J. Virol. (2005) 79(21):13778-13793.
   PubMed Web of Science ®Google Scholar
• SCHERING PLOUGH. Intron A – package insert (2002).
   Google Scholar
• CAULI C, SERRA G, CHESSA L et al.: Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. Haematologica (2006) 91(Suppl. 6):ECR26.
   PubMedGoogle Scholar
• DUVIC M, SHERMAN ML, WOOD GS et al.: A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J. Am. Acad. Dermatol. (2006) 55(5):807-813.
   PubMed Web of Science ®Google Scholar
• CAPURON L, HAUSER P, HINZE-SELCH D, MILLER AH, NEVEU PJ: Treatment of cytokine-induced depression. Brain Behav. Immun. (2002) 16(5):575-580.
   PubMed Web of Science ®Google Scholar
• WICHERS M, MAES M: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. (2002) 5(4):375-388.
   PubMed Web of Science ®Google Scholar
• SCHAEFER M, ENGELBRECHT MA, GUT O et al.: Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26(4):731-746.
   PubMed Web of Science ®Google Scholar
• US FDA. Summary for basis of approval: interferon alfa-2b, recombinant (Intron A) (1986).
   Google Scholar
• CHANG AE, ROSENBERG SA: Overview of interleukin-2 as an immunotherapeutic agent. Semin. Surg. Oncol. (1989) 5(6):385-390.
   PubMed Web of Science ®Google Scholar
• CHIRON CORPORATION. Proleukin package insert (2005).
   Google Scholar
• US FDA. Summary basis of approval: Proleukin (1992).
   Google Scholar
• ANDERSON TD, HAYES TJ, POWERS GD, GATELY MK, TUDOR R, RUSHTON A: Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int. Rev. Exp. Pathol. (1993) 34(Pt A):57-77.
   PubMedGoogle Scholar
• HARADA Y, YAHARA I: Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int. Rev. Exp. Pathol. (1993) 34(Pt A):37-55.
   PubMedGoogle Scholar
• GATELY MK, ANDERSON TD, HAYES TJ: Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J. Immunol. (1988) 141(1):189-200.
   PubMed Web of Science ®Google Scholar
• PEACE DJ, CHEEVER MA: Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J. Exp. Med. (1989) 169(1):161-173.
   PubMed Web of Science ®Google Scholar
• GRIMM EA, MAZUMDER A, ZHANG HZ, ROSENBERG SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. (1982) 155(6):1823-1841.
   PubMed Web of Science ®Google Scholar
• RAFI AQ, ZEYTUN A, BRADLEY MJ et al.: Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J. Immunol. (1998) 161(6):3077-3086.
   PubMed Web of Science ®Google Scholar
• RAFI-JANAJREH AQ, CHEN D, SCHMITS R et al.: Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J. Immunol. (1999) 163(3):1619-1627.
   PubMed Web of Science ®Google Scholar
• LENTSCH AB, MILLER FN, EDWARDS MJ: Interleukin-2-induced hepatic injury involves temporal patterns of cell adhesion in the microcirculation. Am. J. Physiol. (1997) 272(4 Pt 1):G727-G731.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA K, MILLER FN, SIMS DE, LENTSCH AB, MIYAZAKI M, EDWARDS MJ: Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res. (1996) 56(3):507-510.
   PubMed Web of Science ®Google Scholar
• BEYERSDORF N, HANKE T, KERKAU T, HUNIG T: CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun. Rev. (2006) 5(1):40-45.
   PubMed Web of Science ®Google Scholar
• LIN CH, HUNIG T: Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur. J. Immunol. (2003) 33(3):626-638.
   PubMed Web of Science ®Google Scholar
• HUNIG T, DENNEHY K: CD28 superagonists: mode of action and therapeutic potential. Immunol. Lett. (2005) 100(1):21-28.
   PubMed Web of Science ®Google Scholar
• KENTER MJ, COHEN AF: Establishing risk of human experimentation with drugs: lessons from TGN-1412. Lancet (2006) 368(9544):1387-1391.
   PubMed Web of Science ®Google Scholar
• BHOGAL N, COMBES R: TGN-1412: time to change the paradigm for the testing of new pharmaceuticals. Altern. Lab. Anim. (2006) 34(2):225-239.
   PubMed Web of Science ®Google Scholar
• NGUYEN DH, HURTADO-ZIOLA N, GAGNEUX P, VARKI A: Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA (2006) 103(20):7765-7770.
   PubMed Web of Science ®Google Scholar
• ICH, Guidance for industry: S6 Preclinical safety evaluation of biotechnology-derived pharmaceuticals, FDA, Editor (1997).
   Google Scholar
• BOELSTERLI UA: Animal models of human disease in drug safety assessment. J. Toxicol. Sci. (2003) 28(3):109-121.
   PubMedGoogle Scholar
• KREJSA C, ROGGE M, SADEE W: Protein therapeutics: new applications for pharmacogenetics. Nat. Rev. Drug Discov. (2006) 5(6):507-521.
   PubMed Web of Science ®Google Scholar
• LODE HN, XIANG R, BECKER JC, GILLIES SD, REISFELD RA: Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. (1998) 80(3):277-292.
   PubMed Web of Science ®Google Scholar
• SONDEL PM, HANK JA, GAN J, NEAL Z, ALBERTINI MR: Preclinical and clinical development of immunocytokines. Curr. Opin Investig. Drugs (2003) 4(6):696-700.
   PubMedGoogle Scholar
• CONNOR JP, FELDER M, HANK J et al.: Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J. Immunother. (2004) 27(3):211-219.
   PubMed Web of Science ®Google Scholar
• GILLIES SD, LAN Y, WILLIAMS S et al.: An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood (2005) 105(10):3972-3978.
   PubMed Web of Science ®Google Scholar
• KING DM, ALBERTINI MR, SCHALCH H et al.: Phase I clinical trial of the immunocytokine EMD-273063 in melanoma patients. J. Clin. Oncol. (2004) 22(22):4463-4473.
   PubMed Web of Science ®Google Scholar
• KO YJ, BUBLEY GJ, WEBER R et al.: Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD-273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J. Immunother. (2004) 27(3):232-239.
   PubMed Web of Science ®Google Scholar
• NIETHAMMER AG, XIANG R, RUEHLMANN JM et al.: Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. (2001) 61(16):6178-6184.
   PubMed Web of Science ®Google Scholar
• CARTER PJ: Potent antibody therapeutics by design. Nat. Rev. Immunol. (2006) 6(5):343-357.
   PubMed Web of Science ®Google Scholar
• TRINCHIERI G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. (2003) 3(2):133-146.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, SHERMAN ML, FISHER GL et al.: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 90(7):2541-2548.
   PubMed Web of Science ®Google Scholar
• RAKHIT A, YEON MM, FERRANTE J et al.: Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin. Pharmacol. Ther. (1999) 65(6):615-629.
   PubMed Web of Science ®Google Scholar
• CEBON J, JAGER E, SHACKLETON MJ et al.: Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. (2003) 3:7.
   PubMedGoogle Scholar
• LITTLE RF, PLUDA JM, WYVILL KM et al.: Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood (2006) 107(12):4650-4657.
   PubMed Web of Science ®Google Scholar
• GORDON MS, NEMUNAITIS J, HOFFMAN R et al.: A Phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood (1995) 85(11):3066-3076.
   PubMed Web of Science ®Google Scholar
• WEBER J, GUNN H, YANG J et al.: A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. (1994) 15(4):292-302.
   PubMed Web of Science ®Google Scholar
• WEBER J, YANG JC, TOPALIAN SL et al.: Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. (1993) 11(3):499-506.
   PubMed Web of Science ®Google Scholar
• WEBER JS: Clinical trials with IL-6. Ann. NY Acad. Sci. (1995) 762:357-358.
   PubMed Web of Science ®Google Scholar
• LENZI R, ROSENBLUM M, VERSCHRAEGEN C et al.: Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin. Cancer Res. (2002) 8(12):3686-3695.
   PubMed Web of Science ®Google Scholar
• GOLLOB JA, MIER JW, VEENSTRA K et al.: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin. Cancer Res. (2000) 6(5):1678-1692.
   PubMed Web of Science ®Google Scholar
• ROBERTSON MJ, MIER JW, LOGAN T et al.: Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. (2006) 12(14 Pt 1):4265-4273.
   PubMed Web of Science ®Google Scholar
• BERLEX. Campath package insert (2004).
   Google Scholar
• ROCHE PHARMACEUTICALS. Roferon-A package insert (2003).
   Google Scholar
• ROCHE PHARMACEUTICALS. Pegasys package insert (2004).
   Google Scholar
• SCHERING PLOUGH. PEG-Intron package insert (2005).
   Google Scholar
• BERLEX. Leukine package insert (2004).
   Google Scholar
• ORTHO BIOTECH. Orthoclone OKT3 package insert (2001).
   Google Scholar
• CHESON BD: Rituximab: clinical development and future directions. Expert Opin. Biol. Ther. (2002) 2(1):97-110.
   PubMed Web of Science ®Google Scholar
• GENENTECH. Rituxan package insert. (2004).
   Google Scholar
• FEINBERG B, KURZROCK R, TALPAZ M, BLICK M, SAKS S, GUTTERMAN JU: A Phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J. Clin. Oncol. (1988) 6(8):1328-1334.
   PubMed Web of Science ®Google Scholar
• CHAPMAN PB, LESTER TJ, CASPER ES et al.: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J. Clin. Oncol. (1987) 5(12):1942-1951.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, BROWN TD, GOODMAN PJ et al.: High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers. Anticancer Drugs (1992) 3(3):211-217.
   PubMed Web of Science ®Google Scholar
• ESMON CT: The impact of the inflammatory response on coagulation. Thromb. Res. (2004) 114(5-6):321-327.
   PubMed Web of Science ®Google Scholar
• GUO RF, WARD PA: Role of C5a in inflammatory responses. Annu. Rev. Immunol. (2005) 23:821-852.
   PubMed Web of Science ®Google Scholar
• LEVI M, VAN DER POLL T: Two-way interactions between inflammation and coagulation. Trends Cardiovasc. Med. (2005) 15(7):254-259.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DJ, NOVINGER MS, EVATT BL, HOOPER WC: TNF-alpha suppresses IL-1 alpha and IL-6 upregulation of C4b-binding protein in HepG-2 hepatoma cells. Thromb. Res. (1996) 81(3):307-314.
   PubMed Web of Science ®Google Scholar
• HOOPER WC, PHILLIPS DJ, EVATT BL: TNF-alpha suppresses IL-6 upregulation of protein S in HepG-2 hepatoma cells. Thromb. Res. (1996) 81(3):315-326.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB Jr, DAHLBACK B, CHANG AC et al.: Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood (1995) 86(7):2642-2652.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI M, SHIMADA K, OZAWA T: Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J. Cell. Physiol. (1990) 144(3):383-390.
   PubMed Web of Science ®Google Scholar
• CVIRN G, GALLISTL S, KOESTENBERGER M, KUTSCHERA J, LESCHNIK B, MUNTEAN W: Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/ protein S system in cord and adult plasma. Thromb. Res. (2002) 105(5):433-439.
   PubMed Web of Science ®Google Scholar
• MOSNIER LO, GRIFFIN JH: Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci. (2006) 11:2381-2399.
   PubMed Web of Science ®Google Scholar
• GUESSOUS F, MARCINKIEWICZ M, POLANOWSKA-GRABOWSKA R et al.: Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Infect. Immun. (2005) 73(12):8306-8316.
   PubMed Web of Science ®Google Scholar
• KASPERSKA-ZAJAC A, ROGALA B: Platelet function in anaphylaxis. J. Investig. Allergol. Clin. Immunol. (2006) 16(1):1-4.
   PubMed Web of Science ®Google Scholar